Finally, we highlight the therapeutic potential of FXN and BDNF delivery through AAV vector serotype 9 or rh10 for diseases such as FA and the potential of the YG8JR model to evaluate the viability of new therapeutic options. The gene discussed is BDNF; the disease is Friedreich ataxia.